Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe Veneto, Italy site listing changed from Padua to Padova (postal code 35128).SummaryDifference0.0%

- Check16 days agoChange DetectedA new publication citation has been added to the Publications section: 'Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5.' This reference provides additional context for the study's reported outcomes but does not modify study design or participant information.SummaryDifference0.0%

- Check23 days agoChange DetectedNapoli, Campania, Italy, 80131 was renamed to Naples, Campania, Italy, 80131 and a Naples listing was added, with the page revision updated to v3.5.0.SummaryDifference0.1%

- Check38 days agoChange DetectedAdded Revision: v3.4.3; removed Revision: v3.4.2.SummaryDifference0.0%

- Check60 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. This appears to be a version control update with no visible changes to study information or page layout.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. This appears to be a minor technical update without changes to the study content or user-facing features.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.